-
PLOS BIOLOGY: Delayed immune response makes older men more susceptible to COVID19.
Time of Update: 2020-09-26
study published On September 8, 2020 in the open-access journal PLOS Biology, Nicole Lieberman and Alexander Greninger of the University of Washington and colleagues found that different immune responses to SARS-CoV-2 may depend on viral load and the timing of infection, depending on age and gender.
-
Nat Cell Biol: What's new! Cells with lower "stickiness" may be more prone to cancer!
Time of Update: 2020-09-26
10, 2020 // -- In a recent study published in the international journal Nature Cell Biology, scientists from the University of Leipzig and others analyzed in detail the structure of tumor tissue and the behavioral characteristics of tumor cells, and the results may help improve cancer diagnosis and the development of future targeted cancer therapies.
-
Sci Trans Med: Probiotic therapy helps treat eczema.
Time of Update: 2020-09-26
September 11, 2020 /--- A study by the National Institutes of Health found that an experimental treatment that modifies the skin microbiome can safely reduce the severity of eczema and improve the quality of life of children under 3 years of age.
-
Immunity: Allergic reactions help fight bacterial infections.
Time of Update: 2020-09-26
the bacteria is a prototype antibiotic-resistant pathogen and has been linked to the development of allergic immune responses in diseases such as asthma and endexual dermatitis.
found that mice with mild Staphylococcus austratic skin infections produced adaptive immune responses and specific IgE antibodies to bacterial components.
-
PLoS Pathog: CoVID19 patient antibody response helps vaccine design.
Time of Update: 2020-09-26
SEPTEMBER 12, 2020 /--- According to a study published September 10 in the journal PLOS Pathogens by Professor Wu Chao of Nanjing University School of Medicine, a comprehensive analysis of antibody responses in COVID-19 patients could provide information for the development of effective vaccines.
-
Nature: Develops a new way to target cancer cells that divide rapidly and do not damage healthy cells.
Time of Update: 2020-09-25
Then the researchers tested a cell division process that interfered with high levels of TRIM37 cells, using a drug called PLC4 inhibitor, which interferes with the protein that makes the central grain, and then added the drug to breast cancer cells carrying normal level TRIM37, with the opposite result: breast cancer cells could no longer divide, and most cells stopped growing or died.
-
Gut: The intestinal bacteria may not be involved in the onset of gestational diabetes in women.
Time of Update: 2020-09-25
September 14, 2020 // -- Maternal overweight and obesity increase an individual's risk of developing gestational diabetes, and recently researchers found that intestinal bacterial composition is direc
-
New drug for systemic sclerosis! Gilead/Galapagos Selective ATX Inhibitor Ziritaxestat Concept Verification Phase 2 study was successful!
Time of Update: 2020-09-25
Dr Walid Abi-Saab, chief medical officer of Galapagos, said: "Following promising activity in the IDF Phase 2 FLORA trial, we are pleased to see that ziritaxestat has achieved a statistically significant improvement in msSS for diffuse SSc (the main endpoint of the NOVESA study).
-
Cancer Cell: Reveals the molecular mechanisms by which interferon gamma directs melanoma patients to respond to cancer immunotherapy.
Time of Update: 2020-09-25
September 14, 2020 // -- In a recent study published in the international journal Cansr Cell, scientists from the University of California and other institutions revealed the molecular mechanisms by w
-
JPR: Analysis of the metabolic properties of the body in PATIENT COVID-19 patients may reveal its multi-organ effects.
Time of Update: 2020-09-25
researchers studied 17 patients who tested positive for COVID-19 using current methods, 25 healthy control individuals with age, gender and BMI matching them (COVID-19 test results were negative), and then analyzed blood samples from participants' bodies, and then measured the levels of lipoproteins, metabolites, and amino acids in these blood samples using MRI spectroscopy and liquid chromatography-mass spectrometry.
-
Stem Cell Rep: Why do men have a higher incidence of colon cancer? It's closely related to intestinal cortectal stem cells!
Time of Update: 2020-09-25
September 14, 2020 // -- In a recent study published in the international journal Stem Cell Reports entitled "Androgen Maintenances Intestinal Homeostasis by Andring BMP Signaling via Intestinal Strom
-
Cell Stem Cell: A new organ-like platform or research that accelerates early lung cancer promises to help develop new potential targeted therapies.
Time of Update: 2020-09-25
researchers say they hope to develop new human and lung organ models for early-stage lung cancer to help develop powerful drug development platforms to help develop new lung cancer treatments.
-
Sci Rep: Scientists hope to diagnose pancreatic cancer as early as possible.
Time of Update: 2020-09-25
September 14, 2020 // -- Pancreatic cancer is rarely detected at an early stage, as symptoms usually do not show until the cancer progresses, and the usual treatments for pancreatic cancer include sur
-
Clinical applications for the treatment of primary dryness syndrome by the acoustic pharmaceutical company "Elamod tablets" were approved.
Time of Update: 2020-09-24
the clinical application was approved, Edsin (Eramod tablets) is expected to become the first drug in the country to treat primary dryness syndrome, which is the first new adaptation to be developed after approval to treat rheumatoid arthritis.
-
Niney percent of lupus patients want to reduce medical costs in the future.
Time of Update: 2020-09-24
survey, 91 per cent of patients felt that the costs of current treatment were a burden on them; Xiaofeng, director of rheumatology immunology at Beijing Concord Hospital, said: "The biggest challenge facing the treatment of SLE disease in China is the lack of medical care and medicine.
-
JAHA: Association between autoimmune vasculitis and atrial fibrillation.
Time of Update: 2020-09-24
conducted a population-based, standardized retrospective case-control study to assess the association between autoimmune vasculitis and atrial fibrillation and all-cause mortality.
77.2%; , autoimmune vasculitis is significantly associated with atrial fibrillation and can independently lead to poor survival outcomes.
-
Transplant anti-host disease (GVHD) new drug development strategy.
Time of Update: 2020-09-24
, reedin is also actively expanding the adaptation of chronic GVHD, and in July this year it was announced that the single-drug phase III trial Reach3 of the BAT treatment group had reached its main endpoint.
-
The third domestic Adamo single anti-injection fluid was approved for listing.
Time of Update: 2020-09-24
Recently, according to the official website of the State Drug Administration information, Cynda bioAdamu single anti-injection was approved for the treatment of strong spina bifida, rheumatoid arthritis and psoriasis and other autoimmune diseases, which is also after Baiotai, Haizheng Pharmaceuticals, the third domestic Adamo single anti-approval enterprises.
-
Ann Rheum Dis: Nidanib's safety and tolerance for systemic sclerosis-related interstitiotic pulmonary disease.
Time of Update: 2020-09-24
study describes the safety and tolerance of Nidanib in systemic sclerosis-associated interstitiotic pulmonary disease (SSc-ILD), as well as dose adjustment for adverse events.
result, nidanib's adverse event characteristics in SSc-ILD patients are consistent with safety and tolerance in idynapathic pulmonary fibrosis.
-
A new drug for Hunter syndrome, the Ado sulfate enzyme beta injection, has been approved in China.
Time of Update: 2020-09-24
Ado sulfate enzyme beta (English trade name: Hunterase) is a recombinant person Adulystic acid-2-sulphate enzyme replacement therapy, developed by GC Pharma, Beihai Kangcheng owns the Chinese interest in the drug.
